The award is given to recognize scientific achievements of individuals at the mid-career level.
| Eligible Period: | 11-24 yrs after terminal degree1 |
| Description: | Late associate-early full professor level, (growing) international reputation, substantive research impact (e.g., citations, impact factors) INS Membership |
| Required: | No |
| Requirements: | 1 nomination letter and 2 letters of support |
| Presentation Yes/No: | Yes, about research |
| Annual/Mid-Year: | Both |
Application Materials: The application should consist of a nominating letter, a CV plus 1-2 letters of support (see criteria). The nominating statements should be written as relating to the specific award for which the member is being nominated (1-2 page max). Nominating statements should be written in English, letters of support may be written in other languages (although English is preferred). Anyone can nominate and write support letters, but we do not accept self-nominations. Please submit all application materials to ins@the-ins.org
Due Date: Nominations may be submitted at any time. Ideally, awards nominations will be received four months prior to the meeting where the award is to be given (either the Annual or Mid-Year Meeting). For an award to be considered for the INS Mid-Year Meeting, please submit nominations by March 31st. For an award to be considered for the INS Annual Meeting, please submit nominations by September 30th of the prior year. Nominations are typically kept under consideration for future meetings if not awarded at a certain meeting (unless the nomination is not eligible).
1 Terminal degree can be either a PhD degree, a master or a certified clinical degree (may vary across countries)
INS 50th Annual Meeting
New Orleans, Virtual Meeting – February 2-4, 2022
Over the past decade, the conceptualization of epilepsy as a network disorder has revolutionized our approach to the study of seizures, as well as psychiatric and cognitive co-morbidities in epilepsy. Brain imaging has been at the forefront of this movement, shifting the focus from one of identifying epileptic lesions to one defining epileptogenic networks. In parallel, the study of cognitive impairments in epilepsy has shifted from the study of isolated cognitive impairments within epilepsy syndromes (e.g., memory impairments in temporal lobe epilepsy; TLE) to one that emphasizes cognitive and psychiatric profiles within and across epilepsy syndromes–or cognitive phenotyping. In this talk, Dr. McDonald will describe a 15- year NIH-funded program of research using advanced, quantitative structural, functional, and diffusion imaging to characterize the neural substrates underlying cognitive co-morbidities in patients with epilepsy.
INS 2021 Mid-Year Meeting
Melbourne, Australia – June 30 – July 3, 2021
Over the past decade, the conceptualization of epilepsy as a network disorder has revolutionized our approach to the study of seizures, as well as psychiatric and cognitive co-morbidities in epilepsy. Brain imaging has been at the forefront of this movement, shifting the focus from one of identifying epileptic lesions to one defining epileptogenic networks. In parallel, the study of cognitive impairments in epilepsy has shifted from the study of isolated cognitive impairments within epilepsy syndromes (e.g., memory impairments in temporal lobe epilepsy; TLE) to one that emphasizes cognitive and psychiatric profiles within and across epilepsy syndromes–or cognitive phenotyping. In this talk, Dr. McDonald will describe a 15- year NIH-funded program of research using advanced, quantitative structural, functional, and diffusion imaging to characterize the neural substrates underlying cognitive co-morbidities in patients with epilepsy.
INS 49th Annual Meeting
San Diego, Virtual Meeting – February 2-5, 2021
INS 2020 Mid-Year Meeting
Virtual Event Meeting – July 1-2, 2020
INS 48th Annual Meeting
Denver, Colorado, USA – February 5-8, 2020
INS 2019 Mid-Year Meeting
Rio de Janeiro, Brazil – July 10-12, 2019
INS 47th Annual Meeting
New York City, New York, USA – February 20-23, 2019
The prevailing hypothesis about the pathogenesis of Alzheimer’s disease (AD) suggests a cascade of biological events initiated by abnormal beta-amyloid processing that leads tau-related neuronal dysfunction, neurodegeneration, and dementia. This conceptualization has directly informed current diagnostic schemes, which have evolved from diagnosing AD based on the characterization of a clinical syndrome to diagnosing AD based on the presence of amyloid and tau biological markers alone.
INS 2018 Mid-Year Meeting
Prague, Czech Republic – July 18-20, 2018
INS 46th Annual Meeting
Washington, D.C, USA – February 14-17, 2018
INS 45th Annual Meeting
New Orleans, Louisiana, USA – February 1-4, 2017
INS 44th Annual Meeting
Boston, Massachusetts, USA – February 3-6, 2016
It is now well established that up to 70% of persons with multiple sclerosis (MS) suffer from cognitive impairment (Chiaravalloti & DeLuca, 2008). Such impairments can have a significant impact on everyday functional activity in persons with MS. Given the frequency and degree of cognitive involvement in persons with MS, and how it affects so many aspects of a person’s life (e.g., vocational, familial, social, emotional, cultural) the need for cognitive rehabilitation therapies and programs is clear.
INS 43rd Annual Meeting
Denver, Colorado, USA – February 4-7, 2015
INS 39th Annual Meeting
Boston, Massachusetts, USA – February 2-5, 2011
INS 31st Annual Meeting
Honolulu, Hawaii, USA – February 5-8, 2003
ATTN: Neurology Admin/INS
175 N. Medical Dr., 5th Floor, Salt Lake City, Utah 84132, USA
